The Cancer Research Collaboration Partners with Diabetes Prevention Program Provider Blue Mesa Health with California Residents in Mind
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The Cancer Research Collaboration (CRC), a non-profit organization dedicated to expanding the availability of cutting-edge cancer research, in partnership with RadNet, Inc. (Nasdaq:RDNT), a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, are, once again, proud to work in conjunction with Blue Mesa Health’s (“Blue Mesa”) Transformdiabetes prevention program.
Since 2016, Blue Mesa’s CDC-recognized diabetes prevention programs Transformand Transformemos have been helping stem the tide of rising chronic disease-related health costs — a situation where approximately one-third of Americans is prediabetic. The programs are based on the Centers for Disease Control and Prevention’s (CDC) landmark National Diabetes Prevention Program. Transformand Transformemos combine software, home health monitoring via wireless scales, activity trackers and remote health coaching to guide participants through a twelve-month lifestyle change program.
Since joining forces earlier this year to deliver the program to patients in New York, CRC, RadNet and Blue Mesa have decided to expand their collaboration to California patients. Similar to NY, the Transformprogram will be provided to California CRC patients who are at risk or are cancer survivors and meet the program criteria. The goal is for participants to lose approximately 5-7% of their body weight and add 150 minutes of moderate physical activity over 52 weeks, which is correlated with a 58% reduction in risk for type 2 diabetes. These are important goals for at-risk patients and breast cancer survivors. Maintaining a healthy BMI can reduce the risk of developing breast cancer and chronic conditions such as type 2 diabetes.
For more information about the partnership or the program, visit: www.cancerresearchcollaboration.org/blue-mesa.
About Blue Mesa Health
Blue Mesa is a digital therapeutics company with headquarters in New York, NY and Vancouver, BC. Blue Mesa provides digital therapeutics programs in over 5 countries and several languages, with programs based on the CDC's National Diabetes Prevention Program. In the United States, employers, health plans, accountable care organizations, and hospital systems are recognizing the return on investment provided by culturally tailored and digitally delivered preventive health programs. Blue Mesa has raised funding from Nimbus Synergies Inc., Pallasite Ventures, Stanley Park Ventures Inc., and publicly traded technology firm Mobio Technologies Inc. and other investors. For more information, visit www.bluemesahealth.com.
About the Cancer Research Collaboration
The Cancer Research Collaboration (CRC) is a non-profit organization dedicated to expanding the availability of cutting-edge cancer research. CRC assists investigators, pharmaceutical companies, and CROs in identifying new agents and technologies for diagnosis and treatment of diseases.
CRC builds collaborations to foster innovation in research, education and supportive programs aimed at benefiting patients living with cancer or moving beyond it. For more information, visit www.cancerresearchcollaboration.org.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 341 owned and/or operated outpatient imaging centers. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. For more information, visit www.radnet.com.
CONTACT: CONTACT: Curtis Duggan, CEO and Co-Founder press@bluemesahealth.com 1.347.468.3343
© 2018 GlobeNewswire, Inc. All Rights Reserved.
MARS Parachutes, Inc. Announces Its Plans For Growth
